Developer docs
API playgroundTry for free, no card

Search company profiles

Adage Capital Management

Full company profile

uuid000037p

Namestring
Adage Capital Management
Legal namestring
Adage Capital Management, L.P.
Company typeenum
Private
Founded yearint
2001
Descriptiontext

Adage Capital Management, L.P. is a Boston-based private investment management firm founded in 2001 that manages equity portfolios — predominantly S&P 500 assets — on behalf of institutional clients, with a stated emphasis on endowments and foundations. The legal entity operates as a limited partnership domiciled in Massachusetts, with a small professional staff of 11–50 employees led by co-founders and Managing Directors Robert Atchinson and Phillip Gross, and Chief Operating Officer and Chief Compliance Officer Daniel Joseph Lehan. Client interaction occurs through a gated, password-protected portal that explicitly serves clients and limited partners, indicating a closed-end, relationship-driven distribution model rather than a retail or open-channel offering.

The firm's revenue model is typical of an institutional asset manager: fees earned on assets under management, with pricing not publicly disclosed. While its core competency is public-equity portfolio management, the firm has visibly expanded its private-markets activity over the October 2025 to June 2026 period, co-investing in at least eight clinical-stage healthcare and biotechnology financings across ophthalmology (Opus Genetics, Ray Therapeutics), obesity and cardiometabolic disease (Kailera Therapeutics, Corxel Pharmaceuticals), precision medicine (Mirador Therapeutics), central nervous system disorders (Ovid Therapeutics), and extracellular protein degradation (Lycia Therapeutics). In one instance — Opus Genetics — Adage acted as lead investor in a $25 million private placement of Series B Non-Voting Convertible Preferred Stock.

Beyond portfolio management, the firm has made a $10 million commitment to UNCF's Project ACCLAIM to prepare HBCU students for careers in asset and investment management, and has sponsored the HBCU Stock Pitch Competition in Boston, signaling a deliberate ecosystem and talent-pipeline initiative. No AI/ML, technology product, or platform offering is disclosed in the source data, and the firm provides no mobile application or public-facing digital service. The operating geography remains concentrated in the Northeast United States, with the firm headquartered at 200 Clarendon Street in Boston.

Short descriptiontext

Adage Capital Management is a Boston-based private investment firm founded in 2001 that manages equity portfolios, predominantly S&P 500 assets, for endowment and foundation clients, and has expanded into clinical-stage healthcare and biotechnology private investments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
institutional asset management, equity portfolio management, biotech venture investing, endowment investment services, limited partnership management
Industry1 code
PRIMARYFSAAAGAG
Insurance General Accounts (Institutional Asset Owners)
Financial & Insurance/Asset & Wealth Management/Asset Management — Institutional (Pensions, Endowments, Sovereign)
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Investment Advice6282
Product category
Institutional Asset Management
Social media profiles1 record
Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Adage Capital Management, L.P. is a Boston-based private investment management firm that manages equity portfolios — primarily S&P 500 and other equity holdings — for institutional clients such as endowments, foundations, and limited partners. The firm also deploys capital as an institutional investor into private company funding rounds, with notable activity in healthcare, biotechnology, and life sciences sectors (e.g., gene therapy, ophthalmology, and obesity treatment companies).

Differentiator
Functional benefit
Problem solved
Product and service2 records
1Institutional Equity Portfolio Management
CategoryInvestment Management
2Private Equity Investment Participation
CategoryPrivate Equity Investing
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment170 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Adage Capital Management

Institutional Asset Managementadagecapital.com

Adage Capital Management is a Boston-based private investment firm founded in 2001 that manages equity portfolios, predominantly S&P 500 assets, for endowment and foundation clients, and has expanded into clinical-stage healthcare and biotechnology private investments.

What Adage Capital Management does

Adage Capital Management, L.P. is a Boston-based private investment management firm founded in 2001 that manages equity portfolios — predominantly S&P 500 assets — on behalf of institutional clients, with a stated emphasis on endowments and foundations. The legal entity operates as a limited partnership domiciled in Massachusetts, with a small professional staff of 11–50 employees led by co-founders and Managing Directors Robert Atchinson and Phillip Gross, and Chief Operating Officer and Chief Compliance Officer Daniel Joseph Lehan. Client interaction occurs through a gated, password-protected portal that explicitly serves clients and limited partners, indicating a closed-end, relationship-driven distribution model rather than a retail or open-channel offering.

The firm's revenue model is typical of an institutional asset manager: fees earned on assets under management, with pricing not publicly disclosed. While its core competency is public-equity portfolio management, the firm has visibly expanded its private-markets activity over the October 2025 to June 2026 period, co-investing in at least eight clinical-stage healthcare and biotechnology financings across ophthalmology (Opus Genetics, Ray Therapeutics), obesity and cardiometabolic disease (Kailera Therapeutics, Corxel Pharmaceuticals), precision medicine (Mirador Therapeutics), central nervous system disorders (Ovid Therapeutics), and extracellular protein degradation (Lycia Therapeutics). In one instance — Opus Genetics — Adage acted as lead investor in a $25 million private placement of Series B Non-Voting Convertible Preferred Stock.

Beyond portfolio management, the firm has made a $10 million commitment to UNCF's Project ACCLAIM to prepare HBCU students for careers in asset and investment management, and has sponsored the HBCU Stock Pitch Competition in Boston, signaling a deliberate ecosystem and talent-pipeline initiative. No AI/ML, technology product, or platform offering is disclosed in the source data, and the firm provides no mobile application or public-facing digital service. The operating geography remains concentrated in the Northeast United States, with the firm headquartered at 200 Clarendon Street in Boston.

Adage Capital Management firmographics

Firmographics
Name
Adage Capital Management
Legal name
Adage Capital Management, L.P.
Website
https://adagecapital.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
51–100 employees
Short description
Adage Capital Management is a Boston-based private investment firm founded in 2001 that manages equity portfolios, predominantly S&P 500 assets, for endowment and foundation clients, and has expanded into clinical-stage healthcare and biotechnology private investments.
Ownership category
akta.pro rank

Adage Capital Management industry classification

Industry
Product category
Institutional Asset Management
NAICS
Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSAAAGAG
Insurance General Accounts (Institutional Asset Owners)
Financial & Insurance/Asset & Wealth Management/Asset Management — Institutional (Pensions, Endowments, Sovereign)

Keywords

  • Institutional asset management
  • Equity portfolio management
  • Biotech venture investing
  • Endowment investment services
  • Limited partnership management

Where Adage Capital Management is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Adage Capital Management business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Adage Capital Management product offering

Product offering

Core offering

Adage Capital Management, L.P. is a Boston-based private investment management firm that manages equity portfolios — primarily S&P 500 and other equity holdings — for institutional clients such as endowments, foundations, and limited partners. The firm also deploys capital as an institutional investor into private company funding rounds, with notable activity in healthcare, biotechnology, and life sciences sectors (e.g., gene therapy, ophthalmology, and obesity treatment companies).

Differentiator

Problem solved

Functional benefit

Products and services

  • Institutional Equity Portfolio Management
  • Private Equity Investment Participation

Companies that use Adage Capital Management

Customer profile

Ideal customer profiles1 record

Adage Capital Management technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Adage Capital Management partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights4 records

Adage Capital Management competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Adage Capital Management social profiles

Digital presence

Adage Capital Management financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Adage Capital Management leadership team

Management profile

Number of profiles

Profiles3 records

Adage Capital Management funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Adage Capital Management M&A and investment

M&A and investment

M&A

Investments170 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adage Capital Management

What does Adage Capital Management do?

Adage Capital Management, L.P. is a Boston-based private investment management firm that manages equity portfolios — primarily S&P 500 and other equity holdings — for institutional clients such as endowments, foundations, and limited partners. The firm also deploys capital as an institutional investor into private company funding rounds, with notable activity in healthcare, biotechnology, and life sciences sectors (e.g., gene therapy, ophthalmology, and obesity treatment companies).

Is Adage Capital Management a public or private company?

Adage Capital Management is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Adage Capital Management founded?

Adage Capital Management was founded in 2001. It employs 51 to 100 people.

Where is Adage Capital Management based?

Adage Capital Management is headquartered in Boston, United States, in the North America region.

Does Adage Capital Management have an API?

No public API is recorded for Adage Capital Management.

What industry is Adage Capital Management in?

Adage Capital Management's product category is Institutional Asset Management. Its primary akta.pro industry code is FSAAAGAG, Insurance General Accounts (Institutional Asset Owners). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioWorldExpedition Therapeutics navigates $115M series BExpedition Therapeutics raised $115 million in a series B financing led by General Atlantic. RA Capital, Vivo Capital, and existing investors including Sofinnova, Novo Holdings, and Sanofi Ventures participated. The round was announced on BioWorld Financings Respiratory Series B U.S.WebrazziBiyoteknoloji şirketi Expedition Therapeutics, 115 milyon dolar yatırım aldıExpedition Therapeutics raised $115 million in a B-series round led by General Atlantic. The funds will advance Phase 2 trials of EXPD-101, a DPP1 inhibitor for COPD, and expand its inflammatory disease portfolio. The company aims to develop oral small-molecule therapies for immune-related conditions.FinSMEsExpedition Therapeutics Raises $115M in Series B FundingExpedition Therapeutics raised $115M in Series B financing led by General Atlantic. The funds will advance its lead DPP1 inhibitor EXPD-101 through Phase 2 clinical development and expand its pipeline for inflammatory diseases.FinSMEsClaris Biotherapeutics Raises $118M in Series B FundingClaris Biotherapeutics raised $118M in Series B financing led by Samsara Biocapital and Catalio Capital Management. The funds will complete clinical trials for CSB-001 in limbal stem cell deficiency and support a planned 2027 pivotal program. The company also aims to enable pre-commercialization activities.Stock TitanLB Pharmaceuticals Announces $150M Private PlacementLB Pharmaceuticals Inc. announced a $150 million private placement through which it will sell approximately 4.3 million shares of common stock and pre-funded warrants to institutional investors at $34.94 per share. The proceeds will fund pipeline expansion of its lead drug candidate LB-102 into new indications including negative symptoms of schizophrenia and Alzheimer's disease agitation/psychosis, as well as for general working capital and corporate purposes. The private placement, expected to close on or about July 30, 2026, includes participation from investors such as Adage Capital Partners, BB Biotech, Janus Henderson Investors, and Leerink Partners and Piper Sandler acting as placement agents.Venture Capital Access OnlineClaris Bio Unveils Development Strategy, Planned Pivotal Study Supported by $118 Million Series B Financing from Top-Tier Investors, and Multiple Leadership AppointmentsClaris Biotherapeutics closed an $118 million Series B financing and appointed Stephen Brady as CEO and Brian Baum as CCO. The funds will support pivotal studies for CSB-001 in limbal stem cell deficiency, planned for 1H 2027, with proof-of-concept results expected in H2 2026.BioSpaceClaris Bio Unveils Development Strategy, Planned Pivotal Study Supported by $118 Million Series B Financing from Top-Tier Investors, and Multiple Leadership AppointmentsClaris Biotherapeutics closed an $118 million Series B financing and appointed Stephen Brady as CEO and Brian Baum as CCO. The funds will support pivotal studies for CSB-001 in limbal stem cell deficiency, planned for 1H 2027, with proof-of-concept results expected in H2 2026.BioSpaceCAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related DisorderCAMP4 Therapeutics received TGA and HREC clearance to start its Phase 1/2 trial of CMP-002 for SYNGAP1-related disorder. The clearance triggers eligibility for up to $50 million in gross proceeds from a second private placement closing within five business days.FinSMEsLycia Therapeutics Raises $75M in Series D FundingLycia Therapeutics raised $75M in Series D funding co-led by Janus Henderson Investors and Balyasny Asset Management. The company will use the funds to advance its lead LYTAC programs, including LCA-0061 for food allergy and LCA-0321 for Graves' disease, to early Phase 1 clinical proof-of-concept.Venture Capital Access OnlineLycia Therapeutics Raises $75 Million in Oversubscribed Financing and Strengthens Leadership Team with Appointment of Chief Financial Officer and General CounselLycia Therapeutics closed an oversubscribed $75 million Series D financing co-led by Janus Henderson Investors and Balyasny Asset Management. Proceeds will advance its LYTAC pipeline, including LCA-0061 for food allergy and LCA-0321 for Graves' disease, toward early clinical proof-of-concept. The company also appointed Amy Bachrodt as CFO and promoted Karen Flick to General Counsel.